ライフサイエンスコーパス: urine volume

1 urinary Na+ excretion and lead to increased urine volume.

2 lution resulting from changes in the overall urine volume.

3 nor with a substantial increase in residual urine volume.

4 d not correlate with creatinine clearance or urine volume.

5 bed to urinary stasis from elevated residual urine volumes.

6 the absence of significant postvoid residual urine volumes.

7 LDD caused a significant increase in urine volume (88 +/- 58 to 115 +/- 70 ml/h, p = 0.02, 95

8 BG9719 was given in addition to furosemide, urine volume additionally increased and there was no det

9 a vasopressin-dependent manner, allowing for urine volume adjustment.

10 The persistent high urine volume after AVP administration was traced to a re

11 er handling, with decreased water intake and urine volume, alongside higher urine osmolality.

12 control mice, Dot1l(AC) mice had 40% higher urine volume and 18% lower urine osmolarity with relativ

13 esulting in an approximately sixfold greater urine volume and a fivefold greater fluid requirement, c

14 In the kidney, SLC14A1 regulates urine volume and concentration whereas in erythrocytes i

15 pared with placebo, KW-3902 increased hourly urine volume and estimated CrCl with peak effects occurr

16 sponded to 24-h dehydration with a decreased urine volume and increased urine osmolality.

17 is diuresis was compensated for by a drop in urine volume and nitrogen excretion after the epinephrin

18 tes, creatinine, plasma renin concentration, urine volume and osmolality, ability to concentrate and

19 Knockout mice had increased urine volume and reduced urine sodium concentration, but

20 ion of the PGI(2) receptor agonist increased urine volume and sodium excretion in mice.

21 Mean 24-h urine volume and sodium excretion were 1964 +/- 1228 mL

22 The coprimary end points were cumulative urine volume and the change in serum cystatin-C in 72 ho

23 Twenty-four-hour urine volume and total uric acid did not differ among th

24 on PP was associated with an improvement in urine volume and urinary excretion of sodium during the

25 5-6), luseogliflozin significantly increased urine volume and urinary glucose excretion (P < 0.001) w

26 re collected for assessing furosemidePK, and urine volume and urine sodium excretion for PD analyses.

27 Urine volume and urine sodium excretion increased signif

28 ithout ibuprofen), a significant increase in urine volume and water intake was observed; urine volume

29 Urine volume and water intake were unchanged in all othe

30 Postvoid residual urine volumes and urine flow rates were not significantl

31 eficient mice had lower BP (11 mmHg), higher urine volume, and increased sodium excretion despite mil

32 es as assessed by plasma glucose level, 24-h urine volume, and levels of glycated hemoglobin.

33 trast, are indistinguishable from +/+ in BP, urine volume, and osmolality.

34 ng arterial pressure, food and water intake, urine volume, and sodium and potassium excretion.

35 ater intake, food consumption, stool weight, urine volume, and sodium excretion are not significantly

36 g high intravesical pressure, large residual urine volume, and voiding difficulty.

37 Sensitivity analyses using urine volume as another index of RKF yielded consistent

38 ccompanied by reduced daily water intake and urine volume, as well as increased urine osmolality last

39 icantly affect body weight, fluid intake, or urine volume, but the 10 mg x kg(-1) x day(-1) dose redu

40 tial kidney response: There was no effect on urine volume, but there was a significant increase of ur

41 collecting duct principal cells and reduced urine volume by 45% after 5 days of treatment in mice wi

42 The ability to determine adequacy of urine volume by creatinine excretion rate (UVcr) was exa

43 an associated increase in postvoid residual urine volume by the combinations, but not a significantl

44 mitations via the normalization of extracted urine volume by the ratio of absorbance at 300 nm to an

45 ntake of caffeine was associated with higher urine volume, calcium, and potassium and with lower urin

46 multiple abnormalities, including increased urine volume, changes in the circadian rhythm of urinary

47 imary end points included 72-hour cumulative urine volume (decongestion end point) and the change in

48 After 4 d of water restriction, urine volume decreased to the same level as in the rats

49 me), the nocturnal polyuria index (nocturnal urine volume divided by 24-hour volume), and nocturnal u

50 data included the nocturia index (nocturnal urine volume divided by maximal voided volume), the noct

51 no significant effect on 72-hour cumulative urine volume (dopamine, 8524 mL; 95% CI, 7917-9131 vs pl

52 ermeable barrier despite large variations in urine volume during bladder filling and voiding.

53 Parenteral support was reduced if 48-hour urine volumes exceeded baseline values by >/= 10%.

54 oses of desmopressin (dDAVP) which decreased urine volume from 10 to 4 I/day.

55 Balance studies revealed increased urine volume, hypertonic plasma, polydipsia, and impaire

56 inine in high-risk patients, and documenting urine volume in acutely ill people to achieve early diag

57 re frequent voiding facilitated by increased urine volume in hydrated patients may be offset by incre

58 A significant increase in urine volume in the water-loaded rats was observed by th

59 concentration (and creatinine to correct for urine volume) in stored samples from 1040 first-trimeste

60 ncreasing salt intake increases drinking and urine volume is widely accepted.

61 Urine volumes measured by a bladder scanner correlated h

62 by a bladder scanner correlated highly with urine volumes measured by bladder catheterization (summa

63 The second was the correlation between urine volumes measured with a bladder scanner and those

64 h 2014) were searched to identify studies of urine volumes measured with a bladder scanner vs those m

65 ing urinary retention, incontinence, wounds, urine volume measurement, urine sample collection, and c

66 Free water reserve [FWR; urine volume (mL/24 h) minus obligatory urine volume (mL

67 FWR; urine volume (mL/24 h) minus obligatory urine volume (mL/24 h)] served as an HS biomarker.

68 no significant effect on 72-hour cumulative urine volume (nesiritide, 8574 mL; 95% CI, 8014-9134 vs

69 her genotype nor IR affected BP, heart rate, urine volume, or albumin excretion.

70 d a significant and dose-related increase in urine volume over 4 h, compared with placebo.

71 ), and nocturnal urine production (nocturnal urine volume per hours slept).

72 During 24 h, increases in urine volume ranged from 1.8 l with placebo to 3.9 l aft

73 Intravenous bumetanide increased urine volume, regardless of the diluent used.

74 urine volume and water intake was observed; urine volume rose from 9.5+/-1.0 to 22.9+/-1.1 ml/d in r

75 A bladder scan for urine volume should be performed to assess patients with

76 analysis (postacquisition normalization) to urine volume, specific gravity and median fold change ar

77 Hemodynamics, gastric intramucosal pH (pHi) urine volumes, urinary sodium excretion, and cimetidine-

78 Urine volume, urine osmolality, and urinary excretion of

79 After we measured the total urine volume (Uvol), the aliquot was stored for the late

80 001) and nesiritide (interaction P=0.039) on urine volume varied by EF group.

81 k women was 0.11 units higher (P = 0.03) and urine volume was 0.24 L less (P = 0.001).

82 In heart failure with reduced EF, urine volume was higher with active treatment versus pla

83 whereas in heart failure with preserved EF, urine volume was lower with active treatment.

84 Urine volume was measured 3 hours after administration o

85 An increase in urine volume was observed with tolvaptan when compared w

86 PVR bladder urine volume was quantified as the largest cross-section

87 However, 6-hour urine sodium and 6-hour urine volume were not different between the two groups.

88 These increases in urine volumes were accompanied by significant increases

89 or were invasive urodynamic studies, and if urine volumes were measured with a bladder scanner and b

90 onditions, plasma and urine osmolalities and urine volumes were similar between CD-KO mice and contro

91 Luseogliflozin significantly increased urine volume, which was associated with significantly in

92 decrease in water intake and an increase in urine volume with surplus osmolyte excretion.

93 V2 receptor blockade increased urine volume without affecting protein excretion.

94 Hydrochlorothiazide increases urine volume without enhancing FDG excretion.